natgillin/translations-raw huggingface dataset:
In vitro studies indicate that lenalidomide is not a substrate of human breast cancer resistance protein (BCRP), multidrug resistance protein (MRP) transporters MRP1, MRP2, or MRP3, organic anion transporters (OAT) OAT1 and OAT3, organic anion transporting polypeptide 1B1 (OATP1B1), organic cation transporters (OCT) OCT1 and OCT2, multidrug and toxin extrusion protein (MATE) MATE1, and organic cation transporters novel (OCTN) OCTN1 and OCTN2. 
(MRP, od engl. multidrug resistance protein) MRP1, MRP2 ili MRP3, transportera organskog aniona (OAT, od engl. organic anion transporter) OAT1 i OAT3, polipeptidnog transportera organskog aniona 1B1 (OATP1B1, od engl. organic anion transporting polypeptide 1B1), transportera organskog kationa (OCT, od engl. organic cation transporter) OCT1 i OCT2, proteina za izbacivanje više lijekova i toksina (MATE, od engl. multidrug and toxin extrusion) MATE1 i novih transportera organskog kationa (OCTN, od engl. organic cation transporters novel) OCTN1 i OCTN2.
Rd vs MPT Rd vs Rd18 Rd18 vs MPT PFS2e (months) Mediana PFS2 time, months (95% CI)b HR [95% CI]c; p-valued 
Rd vs MPT Rd vs Rd18 Rd18 vs MPT PFS2e (mjeseci) Medijana trajanja PFS2-a, mjeseci (95 % CI)b HR [95 % CI]c; p-vrijednostd
Haemorrhagic disorders are listed under several system organ classes: Blood and lymphatic system disorders; nervous system disorders (intracranial haemorrhage); respiratory, thoracic and mediastinal disorders (epistaxis); gastrointestinal disorders (gingival bleeding, haemorrhoidal haemorrhage, rectal haemorrhage); renal and urinary disorders (haematuria); injury, poisoning and procedural complications (contusion) and vascular disorders (ecchymosis). 
Hemoragijski poremećaji navedeni su pod nekoliko klasifikacija organskih sustava: poremećaji krvi i limfnog sustava; poremećaji živčanog sustava (intrakranijalno krvarenje); poremećaji dišnog sustava, prsišta i sredoprsja (epistaksa); poremećaji probavnog sustava (krvarenje iz desni, krvarenje iz hemoroida, rektalno krvarenje); poremećaji bubrega i mokraćnog sustava (hematurija); ozljede, trovanja i proceduralne komplikacije (kontuzija) i krvožilni poremećaji (ekhimoze).
• Fever, chills, sore throat, cough, mouth ulcers or any other symptoms of infection including within the bloodstream (sepsis) 
• Vrućicu, zimicu, bolno grlo, kašalj, čireve u ustima ili bilo koje druge simptome infekcije uključujući onu u krvotoku (tzv. sepsu)
For male patients taking lenalidomide, pharmacokinetic data has demonstrated that lenalidomide is present in human semen at extremely low levels during treatment and is undetectable in human semen 3 days after stopping the substance in the healthy subject (see section 5.2). 
Za muške bolesnike koji uzimaju lenalidomid, farmakokinetički podaci su pokazali da je lenalidomid prisutan u ljudskoj spermi u iznimno niskim koncentracijama tijekom liječenja te se ne može detektirati u ljudskoj spermi 3 dana nakon prekida uzimanja tvari u zdravih ispitanika (vidjeti dio 5.2).
Time to progression Median [95% CI], weeks 
Vrijeme do napredovanja bolesti Medijan [95 % CI], tjedni
Co-administration of multiple 10 mg doses of lenalidomide had no effect on the single dose pharmacokinetics of R- and S- warfarin. 
Istodobna primjena ponovljenih doza od 10 mg lenalidomida nije imala učinka na farmakokinetiku pojedinačne doze R- i S- varfarina.
The updated PFS, using a cut-off of 1 February 2016 (96.7 months follow up) continues to show a PFS advantage: HR = 0.57 (95% CI 0.47, 0.68; p < 0.001). 
Ažurirani PFS, do zaključnog datuma podataka 1. veljače 2016. (96,7 mjeseci praćenja) i dalje pokazuje prednost PFS-a: HR = 0,57 (95 % CI 0,47; 0,68; p <0,001).
• That Lenalidomide Accord may cause neutropenia and thrombocytopenia and the need for regular blood tests 
• da Lenalidomid Accord može izazvati neutropeniju i trombocitopeniju te da je neophodno redovito obavljanje krvnih pretraga
The results indicate that as renal function decreases (< 50 mL/min), the total lenalidomide clearance decreases proportionally resulting in an increase in AUC. 
Rezultati pokazuju da se ukupni klirens lenalidomida smanjuje proporcionalno smanjenju bubrežne funkcije (< 50 mL/min), što rezultira porastom u AUC-u.
The most serious adverse reactions observed more frequently in lenalidomide/dexamethasone than placebo/dexamethasone combination were: 
Najozbiljnije nuspojave, češće opažene u kombinaciji lenalidomid/deksametazon nego placebo/deksametazon, bile su:
• Passing large amount of urine with bone pain and weakness, which may be symptoms of a kidney disorder (Fanconi syndrome) 
• prekomjerno mokrenje s bolom u kostima i slabošću, što mogu biti simptomi poremećaja bubrega (Fanconijev sindrom)
Newly diagnosed multiple myeloma - in patients who have had a bone marrow transplant Lenalidomide Accord is used on its own as maintenance therapy after patients have recovered enough following a bone marrow transplant. 
Novodijagnosticirani multipli mijelom - u bolesnika u kojih je provedena transplantacija koštane srži Lenalidomid Accord se primjenjuje samostalno kao terapija održavanja nakon odgovarajućeg oporavka poslije transplantacije koštane srži.
AMT = antimyeloma therapy; CI = confidence interval; CR = complete response; d = low-dose dexamethasone; HR = hazard ratio; IMWG = International Myeloma Working Group; IRAC = Independent Response Adjudication Committee; M = melphalan; max = maximum; min = minimum; NE = not estimable; OS = overall survival; P = prednisone; PFS = progression-free survival; PR = partial response; R = lenalidomide; Rd = Rd given until documentation of progressive disease; Rd18 = Rd given for 18 cycles; SE = standard error; T = thalidomide; VGPR = very good partial response; vs = versus. 
Independent Response Adjudication Committee); M = melfalan; maks = maksimum; min = minimum; NP = nije procjenjivo; OS = ukupno preživljenje (engl. overall survival); P = prednizon; PFS = preživljenje bez napredovanja bolesti (engl. progression-free survival); PR = djelomični odgovor (engl. partial response); R = lenalidomid; Rd = Rd davan do dokumentirane progresivne bolesti; Rd18 = Rd davan 18 ciklusa; SE = standardna greška (engl. standard error); T = talidomid; VGPR = vrlo dobar djelomični odgovor (engl. very good partial response); vs = naspram (engl. versus)
• Brochure for women patients who are not of childbearing potential 
• Knjižice za bolesnice koje nisu u reproduktivnoj dobi
7x1 hard capsules 
7x1 tvrda kapsula
Anaemia ◊, Haemorrhagic disorder^, Leucopenias 
anemija◊, hemoragijski poremećaj^, leukopenije
The major dose limiting toxicities (DLT )of lenalidomide include neutropenia and thrombocytopenia. 
Glavne toksičnosti koje ograničavaju dozu lenalidomida uključuju neutropeniju i trombocitopeniju.
• That if his partner becomes pregnant whilst he is taking Lenalidomide Accord or shortly after he has stopped taking Lenalidomide Accord he should inform his treating doctor immediately 
• ako njegova partnerica zatrudni dok on uzima Lenalidomid Accord ili ubrzo nakon prestanka uzimanja lijeka Lenalidomid Accord, odmah treba obavijestiti svog liječnika.
The recommended starting dose of lenalidomide is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles. 
Preporučena početna doza lenalidomida iznosi 25 mg peroralno jednom dnevno od 1. do 21. dana u ponavljajućim 28-dnevnim ciklusima.
The pharmacokinetics of lenalidomide was studied in subjects with renal impairment due to nonmalignant conditions. 
Farmakokinetika lenalidomida ispitana je u ispitanika s funkcijom bubrega oštećenom zbog stanja koja nisu bila zloćudne naravi.
The serious adverse reactions observed more frequently (≥5%) with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance (MPR+R) or melphalan, prednisone and lenalidomide followed by placebo (MPR+p) than melphalan, prednisone and placebo followed by placebo (MPp+p) were: 
Ozbiljne nuspojave opažene su češće (≥ 5 %) uz melfalan, prednizon i lenalidomid nakon čega je slijedila terapija održavanja lenalidomidom (MPR+R) ili uz melfalan, prednizon i lenalidomid nakon čega je slijedio placebo (MPR+p), nego uz melfalan, prednizon i placebo nakon čega je slijedio placebo (MPp+p), a bile su:
Co-administration of single or multiple doses of dexamethasone (40 mg once daily) has no clinically relevant effect on the multiple dose pharmacokinetics of lenalidomide (25 mg once daily). 
Istodobna primjena pojedinačne doze ili ponovljenih doza deksametazona (40 mg jedanput na dan) nije imala klinički značajan učinak na farmakokinetiku ponovljenih doza lenalidomida (25 mg jedanput na dan).
Common Erectile dysfunction 
Često erektilna disfunkcija
• you should take lenalidomide at about the same time on the scheduled days. 
• Lenalidomid treba uzimati otprilike u isto vrijeme svakoga dana određenog za uzimanje lijeka.
CI = confidence interval; CR = complete response; HR = Hazard Rate; M = melphalan; NE = not estimable; OS = overall survival; p = placebo; P = prednisone; 
CI = interval pouzdanosti; CR = potpuni odgovor; HR = omjer hazarda; M = melfalan; NE = nije procjenjivo; OS = ukupno preživljenje; p = placebo; P = prednizon;
Common Febrile neutropenia^,◊, 
Često febrilna neutropenija^,◊,
Pneumonia◊, Bacterial, viral and fungal infections (including opportunistic infections)◊, Cellulitis◊, Sepsis◊, Bronchitis◊ 
Često pneumonija◊, bakterijske, virusne i gljivične infekcije (uključujući oportunističke infekcije)◊, celulitis◊, sepsa◊, bronhitis◊
Lenalidomide induced in monkeys malformations similar to those described with thalidomide (see sections 4.6 and 5.3). 
Lenalidomid je u majmuna inducirao malformacije slične onima opisanim s talidomidom (vidjeti dijelove 4.6 i 5.3).
Common Pulmonary embolism◊,* 
Često plućna embolija◊,*
The demographics and disease-related baseline characteristics of the patients were well balanced in all 3 arms. 
Demografski podaci i uz bolest povezane karakteristike bolesnika prije ispitivanja bili su dobro ujednačeni u sve 3 skupine.
A medically supervised pregnancy test should be repeated every 4 weeks, including 4 weeks after the end of treatment, except in the case of confirmed tubal sterilisation. 
Test na trudnoću pod liječničkim nadzorom treba ponavljati svaka 4 tjedna, uključujući 4 tjedna nakon završetka liječenja, osim u slučaju potvrđenog podvezivanja jajovoda.
Interrupt lenalidomide treatment 
Privremeno prekinuti liječenje lenalidomidom
Leukocytoclastic vasculitis, Drug Reaction with Eosinophilia and Systemic Symptoms^ 
Nepoznato leukocitoklastični vaskulitis, reakcija na lijek s eozinofilijom i sistemskim simptomima^
• Description of the patient card and its necessity 
• opis kartice za bolesnika te zašto je ona potrebna
Fatigue◊, Oedema (including peripheral oedema), Pyrexia◊, Asthenia, Influenza like illness syndrome (including pyrexia, cough, myalgia, musculoskeletal pain, headache and rigors) 
Vrlo često umor◊, edem, (uključujući periferni edem), pireksija◊, astenija, sindrom bolesti nalik gripi (uključujući pireksiju, kašalj, mialgiju, mišićnokoštanu bol, glavobolju i tresavicu)
Patients who completed 9 cycles or who were unable to complete 9 cycles due to intolerance proceeded to maintenance therapy starting with lenalidomide 10 mg orally on days 1 to 21 of repeated 28-day cycles until disease progression. 
Bolesnici koji su završili 9 ciklusa ili nisu mogli završiti 9 ciklusa zbog nepodnošenja, nastavili su s terapijom održavanja počevši s lenalidomidom 10 mg peroralno od 1. do 21. dana u ponavljajućim 28-dnevnim ciklusima do progresije bolesti.
Congestive cardiac failure◊, Tachycardia, Cardiac failure◊, Myocardial ischemia◊ 
kongestivno zatajenje srca◊, tahikardija, zatajenje srca◊, ishemija miokarda◊
The primary efficacy endpoint in the study was progression free survival (PFS) from randomisation to the date of progression or death, whichever occurred first; the study was not powered for the overall survival endpoint. 
U ispitivanju, mjera primarnog ishoda djelotvornosti bilo je preživljenje bez progresije bolesti (engl. progression-free survival, PFS) od randomizacije do datuma progresije bolesti ili smrti, štogod se dogodilo prije; ispitivanje nije omogućilo ishod ukupnog preživljenja.
Psychiatric Disorders 
Psihijatrijski poremećaji
• Chest pain or leg pain 
• Bol u prsnom košu ili nogama
It is not known whether lenalidomide is excreted in human milk. 
Nije poznato izlučuje li se lenalidomid u majčino mlijeko.
In an analysis of PFS, PFS2, OS using a cut-off of April 2013 where the median follow up time for all surviving subjects was 62.4 months, the results of the study are presented in Table 6: 
U tablici 6 prikazani su podaci ispitivanja u kojem su se analizirali podaci za PFS, PFS2 i OS do zaključnog datuma podataka u travnju 2013., gdje je medijan vremena praćenja za sve preživjele ispitanike iznosio 62,4 mjeseca.
• Levonorgestrel-releasing intrauterine system (IUS) 
• intrauterini uložak za otpuštanje levonorgestrela
Multiple myeloma - in patients who have had treatment before Lenalidomide Accord is taken together with an anti-inflammatory medicine called ‘dexamethasone'. 
Multipli mijelom - u bolesnika koji su prethodno liječeni Lenalidomid Accord se uzima zajedno s protuupalnim lijekom pod nazivom ‘deksametazon'
Lenalidomide induced in monkey malformations similar to those described with thalidomide (see section 5.3). 
Lenalidomid je u majmuna prouzročio malformacije slične onima opisanim s talidomidom (vidjeti dio 5.3).
• If your partner becomes pregnant whilst you are taking lenalidomide , you should inform your doctor immediately. 
• Ako Vaša partnerica zatrudni dok Vi uzimate lenalidomid, odmah obavijestite svog liječnika.
The data were not adjusted according to the longer duration of treatment in the lenalidomide-containing arms continued until disease progression versus the placebo arms in the pivotal multiple myeloma studies (see section 5.1). 
Podaci nisu bili prilagođeni za dulje trajanje liječenja u skupinama koje su primale lenalidomid do progresije bolesti naspram skupina koje su primale placebo u ključnim ispitivanjima multiplog mijeloma (vidjeti dio 5.1).
In total 460 patients were randomised: 231 patients to lenalidomide and 229 patients to placebo. 
bolesnika: 231 bolesnik u skupinu lenalidomida i 229 bolesnika u skupinu placeba.
Lenalidomide treatment should be supervised by a physician experienced in the use of anti-cancer therapies. 
Liječenje lenalidomidom treba nadzirati liječnik iskusan u primjeni protutumorske terapije.
Hepatic failure, including fatal cases, has been reported in patients treated with lenalidomide in combination therapy: acute hepatic failure, toxic hepatitis, cytolytic hepatitis, cholestatic hepatitis, and mixed cytolytic/cholestatic hepatitis have been reported. 
Zatajenje jetre, uključujući smrtne slučajeve, prijavljeno je u bolesnika liječenih lenalidomidom u kombiniranoj terapiji: prijavljeno je akutno zatajenje jetre, toksični hepatitis, citolitički hepatitis, kolestatski hepatitis i mješoviti citolitički/kolestatski hepatitis.
Muscular weakness, Bone pain◊, Musculoskeletal and connective tissue pain and discomfort (including back pain◊) 
Često mišićna slabost, bol u kostima◊, bol i nelagoda u mišićnokoštanom i vezivnom tkivu (uključujući bol u leđima◊)
Common Hypotension◊, Hypertension, Ecchymosis^ 
Često hipotenzija◊, hipertenzija, ekhimoza^
Rare Tumour lysis syndrome 
Rijetko sindrom lize tumora
Common Febrile neutropenia^,◊, Pancytopenia◊ 
Često febrilna neutropenija^,◊, pancitopenija◊
If pregnancy occurs in a woman treated with lenalidomide, treatment must be stopped and the patient should be referred to a physician specialised or experienced in teratology for evaluation and advice. 
Ako žena liječena lenalidomidom zatrudni, liječenje se mora prekinuti i bolesnicu uputiti liječniku specijaliziranom ili iskusnom u teratologiji na pregled i savjetovanje.
bone pain, joint pain, tiredness, generalised swelling including swelling of your arms and legs 
bol u kostima, bol u zglobovima, umor, opće oticanje uključujući oticanje ruku i nogu
Infection◊, Urinary tract infection◊,*, Lower respiratory tract infection, Lung infection◊ 
Često infekcija◊, infekcija mokraćnog sustava◊,*, infekcija donjih dišnih puteva, infekcija pluća◊
Lenalidomide received by subjects in the placebo arm who crossed over prior to PD upon study unblinding was not considered as a second-line therapy. 
Lenalidomid, koji su primili ispitanici iz skupine placeba koji su bili prešli u skupinu lenalidomida prije progresije bolesti, po otkrivanju slijepe šifre ispitivanja nije se smatrao terapijom druge linije.
In clinical trials in previously treated myeloma patients with lenalidomide/dexamethasone compared to controls, mainly comprising of basal cell or squamous cell skin cancers. 
U kliničkim ispitivanjima prethodno liječenih bolesnika s mijelomom koji su primali lenalidomid/deksametazon u usporedbi s kontrolnim skupinama, od kojih je većina imala rak bazalnih ili pločastih stanica kože.
Because of the increased risk of venous thromboembolism in patients with multiple myeloma taking lenalidomide in combination therapy, and to a lesser extent in patients with multiple myeloma, taking lenalidomide monotherapy, combined oral contraceptive pills are not recommended (see also section 4.5). 
Zbog povećanog rizika od venske tromboembolije u bolesnika s multiplim mijelomom koji uzimaju lenalidomid u kombiniranoj terapiji, a u manjoj mjeri u bolesnika s multiplim mijelomom na monoterapiji lenalidomidom, ne preporučuju se kombinirane peroralne kontracepcijske tablete (vidjeti također dio 4.5).
There are no phase III trial experiences with End Stage Renal Disease (ESRD) (CLcr < 30 mL/min, requiring dialysis). 
Nema iskustava iz ispitivanja faze III s bolesnicima u terminalnom stadiju bubrežne bolesti (Clcr < 30 mL/min, potrebna je dijaliza).
The median duration of treatment was 44.0 weeks (min: 0.1, max: 254.9) for len/dex and 23.1 weeks (min: 0.3, max: 238.1) for placebo/dex. 
Medijan trajanja liječenja iznosio je 44,0 tjedana (min: 0,1, maks: 254,9) za len/deks te 23,1 tjedan (min: 0,3, maks: 238,1) za placebo/deks.
Patients with a history of severe rash associated with thalidomide treatment should not receive lenalidomide. 
Bolesnici s anamnezom teškog osipa koji je povezan s liječenjem talidomidom ne smiju primati lenalidomid.
Cases of allergic reaction/hypersensitivity reactions have been reported in patients treated with lenalidomide (see section 4.8). 
U bolesnika liječenih lenalidomidom prijavljeni su slučajevi alergijskih reakcija/reakcija preosjetljivosti (vidjeti dio 4.8).
• Widespread rash, high body temperature, liver enzyme elevations, blood abnormalities (eosinophilia), enlarged lymph nodes and other body organs involvement (Drug Reaction with eosinophilia and Systemic Symptoms which is also known as DRESS or drug hypersensitivity syndrome). 
• široko rasprostranjen osip, visoka tjelesna temperatura, povišeni jetreni enzimi, odstupanja u rezultatima krvnih pretraga (eozinofilija), povećani limfni čvorovi i zahvaćenost drugih tjelesnih organa (reakcija na lijek s eozinofilijom i sistemskim simptomima (DRESS), poznata i kao sindrom preosjetljivosti na lijek).
Complete response and overall response rates in the len/dex arm were also significantly higher than the placebo/dex arm in both studies. 
Potpuni odgovor i ukupne stope odgovora u skupini koja je primala len/deks bile su također značajno više nego u skupini koja je primala placebo/deks za oba ispitivanja.
• Understand that if his female partner becomes pregnant whilst he is taking lenalidomide or shortly after he has stopped taking lenalidomide , he should inform his treating physician immediately and that it is recommended to refer the female partner to a physician specialised or experienced in teratology for evaluation and advice. 
• Shvaćaju da u slučaju da partnerica zatrudni za vrijeme njegova liječenja lenalidomidom ili kratko nakon što je prestao uzimati lenalidomid, treba odmah obavijestiti nadležnog liječnika te da se preporučuje partnericu uputiti liječniku specijaliziranom za teratologiju ili s iskustvom u teratologiji zbog procjene i savjeta.
• Use in patients with hepatic and/or renal impairment 
• primjena kod bolesnika s oštećenjem jetre i/ili bubrega
Lenalidomidea 
Lenalidomida
When neutrophils 
Kada broj neutrofila
• Wheezing, breathlessness or a dry cough, which may be symptoms caused by inflammation of the tissue in the lungs. 
• piskanje, nedostatak zraka ili suhi kašalj, što mogu biti simptomi prouzročeni upalom tkiva pluća
CI = confidence interval; HR = hazard ratio; max = maximum; min = minimum; NE = not estimable; OS = overall survival; PFS = progression-free survival; 
CI = interval pouzdanosti; HR = omjer hazarda; maks = maksimum; min = minimum; NP = nije procjenjivo; OS = ukupno preživljenje; PFS = preživljenje bez progresije bolesti;
An absence of the intermediate lobe of the lung was observed at 10 and 20 mg/kg/day with dose dependence and displaced kidneys were observed at 20 mg/kg/day. 
Odsutnost srednjeg režnja pluća ovisna o dozi primijećena je pri dozama od 10 i 20 mg/kg/dan, a poremećaj lokacije bubrega pri dozi od 20 mg/kg/dan.
Lenalidomide is present in human semen at extremely low levels during treatment and is undetectable in human semen 3 days after stopping the substance in the healthy subject (see section 5.2). 
Lenalidomid je prisutan u ljudskoj spermi u iznimno niskim koncentracijama tijekom liječenja te se ne može detektirati u ljudskoj spermi 3 dana nakon prekida uzimanja tvari kod zdravih ispitanika (vidjeti dio 5.2).
Co-administration of a single 25 mg dose of warfarin had no effect on the pharmacokinetics of lenalidomide. 
Istodobna primjena pojedinačne doze od 25 mg varfarina nije imala učinka na farmakokinetiku lenalidomida.
For patients older than 75 years of age treated with lenalidomide in combination with dexamethasone, the starting dose of dexamethasone is 20 mg once daily on days 1, 8, 15 and 22 of each 28-day treatment cycle. 
Za bolesnike starije od 75 godina liječene lenalidomidom u kombinaciji s deksametazonom, početna doza deksametazona iznosi 20 mg jedanput na dan, 1., 8., 15. i 22. dana svakog 28-dnevnog ciklusa liječenja.
Lenalidomide is structurally related to thalidomide. 
Lenalidomid je strukturno srodan talidomidu.
Newly diagnosed multiple myeloma - in patients who cannot have a bone marrow transplant Lenalidomide Accord is taken with other medicines: 
Novodijagnosticirani multipli mijelom - u bolesnika u kojih nije moguća transplantacija koštane srži Lenalidomid Accord se uzima s drugim lijekovima:
The recommended starting dose is lenalidomide 10 mg orally once daily continuously (on days 1 to 28 of repeated 28-day cycles) given until disease progression or intolerance. 
Preporučena početna doza lenalidomida iznosi 10 mg peroralno jednom dnevno bez prekida (od 1. do 28. dana u ponavljajućim 28-dnevnim ciklusima), a daje se do napredovanja bolesti ili nepodnošenja liječenja.
Therefore, erythropoietic agents, or other agents that may increase the risk of thrombosis, such as hormone replacement therapy, should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone. 
Eritropoetske lijekove ili druge lijekove koji mogu povećati rizik od tromboze, poput hormonskog nadomjesnog liječenja, treba stoga primjenjivati oprezno u bolesnika s multiplim mijelomom koji primaju lenalidomid s deksametazonom.
The risk of occurrence of hematologic SPM must be taken into account before initiating treatment with lenalidomide either in combination with melphalan or immediately following high-dose melphalan and ASCT. 
Rizik od pojave drugih primarnih hematoloških zloćudnih bolesti mora se uzeti u obzir prije početka liječenja lenalidomidom, bilo u kombinaciji s melfalanom ili neposredno nakon visoke doze melfalana i transplantacije autolognih matičnih stanica.